CG
TVTX icon

Cutler Group’s Travere Therapeutics TVTX Stock Holding History

Cutler Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7,500
Closed -$10K – 5688
2022
Q1 		$10K Buy
7,500
+6,400
+582% +$170K ﹤0.01% 3638
2021
Q4 		$1K Sell
1,100
-800
-42% -$22.5K ﹤0.01% 5150
2021
Q3 		$2K Buy
+1,900
New +$34.9K ﹤0.01% 5112
2017
Q4 		– Sell
-10,800
Closed -$10K – 5943
2017
Q3 		$10K Buy
10,800
+4,500
+71% +$99.1K ﹤0.01% 3827
2017
Q2 		$3K Sell
6,300
-6,200
-50% -$112K ﹤0.01% 5321
2017
Q1 		$7K Sell
12,500
-100
-0.8% -$1.96K ﹤0.01% 4433
2016
Q4 		$23K Sell
12,600
-44,000
-78% -$900K ﹤0.01% 3330
2016
Q3 		$175K Buy
56,600
+40,400
+249% +$769K 0.01% 1332
2016
Q2 		$70K Buy
16,200
+12,600
+350% +$204K ﹤0.01% 2029
2016
Q1 		$1K Sell
3,600
-31,700
-90% -$481K ﹤0.01% 6144
2015
Q4 		$8K Buy
+35,300
New +$705K ﹤0.01% 4436

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Cutler Group's TVTX Position: Q1 2024 in Review

Cutler Group reduced its Travere Therapeutics (TVTX) stake by 30% in Q1 2024, selling an estimated $5.06K and leaving 1,400 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #1290.

Cutler Group first reported a position in TVTX in Q4 2015 and has held it in 26 quarters since. The position peaked at $482K in Q4 2015. 175 funds tracked by Wall St. Rank hold TVTX as of Q1 2024.

  • Cutler Group held 1,400 shares of Travere Therapeutics worth $10K as of Q1 2024.
  • Cutler Group sold 600 Travere Therapeutics shares in Q1 2024, an estimated $5.06K.
  • Travere Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1290 holding.
  • Cutler Group first reported a position in Travere Therapeutics in Q4 2015 and has held it in 26 quarters since.
  • Cutler Group's Travere Therapeutics position peaked at $482K in Q4 2015.
  • 175 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.